Methods for treating disorders using NMDA NR2B-subtype selective antagonist

Details for Australian Patent Application No. 2009228660 (hide)

Owner Evotec Neurosciences GmbH

Inventors Tasker, Timothy; Kemp, John Alan

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2009228660

PCT Pub. Number WO2009/118187

Priority 61/040,087 27.03.08 US

Filing date 26 March 2009

Wipo publication date 1 October 2009

International Classifications

C07D 403/06 (2006.01) Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group

A61K 31/505 (2006.01) - Pyrimidines

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

A61P 25/28 (2006.01) Drugs for disorders of the nervous system

Event Publications

18 November 2010 PCT application entered the National Phase

  PCT publication WO2009/118187 Priority application(s): WO2009/118187

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009228664-Therapy for vitiligo

2009228652-Process for the synthesis of ethynylcyclopropane